Table 2

Clinical and treatment-related characteristics of HIV-infected adolescents receiving antiretroviral therapy in public hospitals, South Ethiopia, 2024

Variables	Categories	Frequency	Percentage
Mode of entry	VCT	77	18.8
	Medical referral/linkage	253	61.9
	Other*	79	19.3
Body mass index for age	<–2 SD	185	45.2
Body mass index for age	≥− 2 SD	224	54.8
Haemoglobin level	<100 g/L	28	6.9
Haemoglobin level	≥100 g/L	381	93.1
WHO clinical staging	I	227	55.5
	II	56	13.7
	III	107	26.1
	IV	19	4.7
History of tuberculosis	Yes	65	15.9
History of tuberculosis	No	344	84.1
Treated for tuberculosis (n=65)	Yes	61	93.9
Treated for tuberculosis (n=65)	No	4	6.1
Treatment regimen for tuberculosis	2SRHZ/4RH	5	7.7
	2HRZE/4RH	55	84.6
	Unknown	5	7.7
History of opportunistic infections other than tuberculosis	Yes	74	18.1
History of opportunistic infections other than tuberculosis	No	335	81.9
Functional status	Working	298	72.9
	Ambulatory	90	22.0
	Bedridden	21	5.1
Disclosure of HIV status to the adolescent	Yes	265	64.8
Disclosure of HIV status to the adolescent	No	144	35.2
Co-trimoxazole Prophylactic Therapy	Yes	227	55.5
Co-trimoxazole Prophylactic Therapy	No	182	44.5
INH	Yes	268	65.5
INH	No	141	34.5
Type of initial regimen	TDF+3TC+EFV	60	14.7
	AZT+3TC+NVP	157	34.4
	TDF+3TC+DTG	69	16.9
	ABC+3TC+DTG	34	8.3
	AZT+3TC+EFV	23	5.6
	Other†	66	16.1
Month on antiretroviral therapy	<1 year	55	13.5
	1–4 years	142	34.7
	≥5 years	212	51.8
Adherence	Good	331	80.9
	Fair	30	7.3
	Poor	48	11.7
Regimen change	Yes	265	64.8
Regimen change	No	144	35.2
Viral load (n=205) in copies/mL	Below 1000	180	87.8
Viral load (n=205) in copies/mL	1000 and above	25	12.2
CD4 count (n=281) in cells/mm³	≤200	50	17.8
	200–350	47	16.7
	≥350	184	65.5

*Other: dried blood spots, index case testing and self-referral.
†Other: ABC+3TC+EFV, ABC+3TC+LPV/r, TDF+3TC+ATV/r.
ABC, abacavir ; ATV, atazanavir; AZT, zidovudine; DTG, dolutegravir; E, ethambutol; EFV, efavirenz; H, isoniazid; INH, isoniazid; LPV/r, lopinavir/ritonavir; NVP, nevirapine; R, rifampicin; S, streptomycin; 3TC, lamivudine; TDF, tenofovir; VCT, Voluntary Counseling and Testing; Z, pyrazinamide.